NCT05125068 - Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

IgA NephropathyIgAN

Interventions

DRUG

AT-1501

AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

Trial Locations (26)

3168

Monash Medical Centre, Clayton

3204

Waikato Hospital, Hamilton

4120

Hawke's Bay Hospital, Hastings

10250

Sri Jayawardanepura General Hospital, Nugegoda

10330

Chulalongkorn University, Pathum Wan

25100

Hospital Tengku Ampuan Afzan (HTAA), Kuantan

43000

Hospital Kajang, Kajang

Hospital Serdang, Kajang

59100

University Malaya Medical Centre (UMMC), Kuala Lumpur

NSW 2170

Liverpool Hospital, Liverpool

Unknown

Western Health, St Albans

University Hospital Centre Sisters of Charity, Zagreb

University Hospital Dubrava Zagreb, Zagreb

Hospital Queen Elizabeth, Kota Kinabalu

University of Santo Tomas Hospital, Sampaloc

Medical University of Bialystok UI, Bialystok

Specjalistyczne Centrum Medyczne, SCM Spółka, Krakow

Hospital de Sagunto, Sagunto

Hospital Clinico San Carlos, Madrid

Hospital Virgen de la Macarena, Seville

Hospital Universitario Miguel Servet, Zaragoza

Prince of Songkla University, Dusit

Phramongkutklao Hospital, Bangkok

Chiang Mai University, Chiang Mai

Kings College Hospital, Camberwell

01000

National Hospital of Sri Lanka, Colombo